The potential for vaccine development against chlamydial infection and disease.
Chlamydia trachomatis and Chlamydia pneumoniae appear to share a common immunobiology with about 80% of their protein coding genes being orthologs. Progress in DNA vaccine development for C. trachomatis suggests that such a subunit approach may prove useful for C. pneumoniae. The recent finding that it is possible to select for chlamydiae with targeted mutations in key metabolic genes together with the new knowledge of the chlamydia genome also suggests that it may be possible to develop live attenuated strains of chlamydiae for use as vaccine.
Brunham
R C
RC
University of British Columbia, Centre for Disease Control, Vancouver, Canada V5Z 4R4.
Zhang
D J
DJ
Yang
X
X
McClarty
G M
GM
D000818:Animals; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology; D002690:Chlamydia Infections / Q000276:immunology / Q000517:prevention & control*; D002692:Chlamydia trachomatis / Q000235:genetics* / Q000276:immunology*; D016993:Chlamydophila pneumoniae / Q000235:genetics / Q000276:immunology*; D015195:Drug Design; D006801:Humans; D051379:Mice; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology
D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA